Loading clinical trials...
Loading clinical trials...
Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Metamorphosis LTD
Cañon City, Colorado, United States
Start Date
September 1, 2022
Primary Completion Date
December 31, 2022
Completion Date
December 31, 2022
Last Updated
April 13, 2023
41
ACTUAL participants
Stellate Ganglion Block
PROCEDURE
Lead Sponsor
Metamorphosis LTD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06631287